based limits for impurities was the international conference on harmonization (ICH) Q3A [2] . This provided an overview of the typical impurities that were found in new drug substances and their controls. Impurities were evaluated based on Glob Abstract Safety based impurity limits are key to the effective reduction and control of impurities in medicinal products. Impurity limits now have a greater focus on daily exposure limits, with the introduction of various approaches, such as permitted daily exposure (PDEs), acceptable the introduction of less than lifetime (LTL) limits for mutagenic impurities, which is based on an application of Haber's law which states that concentration and exposure times are both critical for assessing likely safety risk to patients. Surprisingly, LTLs have not been applied to the other A recent publication has suggested that a LTL limit for general impurities of 5 mg or 0.7% (whichever is lower), for clinical studies with durations of less than 6 months is warranted. ICH S9 indicated that there was no additional impact on patient safety for impurities where the parent drug substance is extremely toxic and impurity levels (even mutagenic impurities) for oncology products could be controlled at higher levels. However, there has been little regulatory appetite for broadening this entirely pragmatic approach to other therapeutic areas, where life expectancy is equally short, i.e. rare diseases.
Introduction
Paracelsus, the medieval physician, who is often viewed appreciate that "the dose makes the poison". This essentially means that very toxic materials can be used therapeutically at very low concentrations and conversely even safe materials can be toxic if overdosed. This in turn led to Haber's law, which basically states that, the incidence and/or severity of any toxic effect is dependent on the total exposure to the toxic agent; that is, the exposure concentration (c) (or dose) multiplied by the duration time (t) of exposure (i.e. c×t). This law is often utilised in setting exposure limits for toxic components. The major caveat, is that establishing acceptable daily intakes (ADIs) for long-term exposures to a toxic substance when only data from short-term studies are available, does require the use of an uncertainty or safety factor.
For example, cancer risk estimates are typically based on the average lifetime daily dose (LDD), which in turn is derived from the total cumulative exposure, using Haber's law, i.e. c×t. Gaylor levels based on shorter term exposure intervals and this takes the form of:
where c and t are the known safe exposure levels(c) based on the longer exposure duration (t) and c' and t' are the projected duration (t'). Haber's law is equally germane to impurities as it is to medicinal products. guidance for qualifying those impurities that were not present, or were present at substantially lower levels, in batches of a new drug substance used in safety and clinical studies". relative retention of 0.9")". The reporting threshold was linked to the capability of the was the limit where the unknown impurity was required to be pre-clinical safety data that "establishes the biological safety of Interestingly, although the derivation of the reporting threshold was linked to method capability, the derivation of fully delineated, apart from linkage with the maximum daily dose of the product. In addition, for those impurities "known to be unusually potent or to produce toxic or unexpected pharmacological effects, the quantitation/detection limit of the analytical procedures should be commensurate with the level at which the impurities should be controlled". Again, the implicit meaning of this statement was never fully articulated, but it was the genesis for the subsequent guidance on mutagenic impurities, initially termed genotoxic impurities [5] .
Similar guidance was provided for impurities typically found in new drug products. These impurities are usually termed degradation products [6] . There was greater delineation of the thresholds in terms of dose (Table 2 ). However, it was never fully explained why the various thresholds, in terms of maximum daily dose, could not be aligned. Thus there is the confusing scenario that the reporting thresholds are above or below 1g; whereas, were also divided into four, but were not aligned with the classes 100mg and <10mg). The other confusing aspect was that the maximum daily dose (mg/day) and the maximum strength of a product (mg) are often not the same value. Thus for instance, the anti-malarial drug quinine sulfate [7] has a maximum therapeutic dose from the product label of 648mg every 8hours, i.e. 1944mg/day; whereas, the highest dose strength are 324mg/capsule. The analysts testing and releasing quinine sulfate capsules will do so on the commercial product (324mg/capsule), not the maximum dose taken by the patient (1944mg/day). In addition, although reporting thresholds are always measured as percentage values and are easily aligned with the data output from the method are measured in either percentage values or mg/day values (Table 3) . Solvents with low toxic potential in man; no health-based exposure limit is needed. Class 3 solvents have PDEs of 50 mg or more per day (corresponding to 5000ppm or 0.5%).
The other aspect of having safety based limits for impurities drug and results in the same limits being proposed irrespective of whether the drug is proscribed pro ne rata (PRN) or as required, e.g. for constipation, mild pain, etc., or through life time treatments, e.g. for treatment of high blood pressure, etc.
ICH Q3A [2] and Q3B [6] were always intended to be only applicable to marketed products, but the regulatory expectations during clinical development often exceed what is actually required. For example, it isn't unusual to see the following expectations [8]:
impurity levels to be established (aligned with ICH Q3A, Q3B, etc)". regulatory guidance enshrined in ICH M3 [10] , actually states to qualify an impurity or degradant, generally these studies are not warranted before phase 3 unless there are changes that pathway, a new degradant formed by interactions between the components of the formulation). In these latter cases, phase 2 or later stages of development".
Residual Solvent Impurities (ICH Q3C)
Although residual solvents are mentioned in ICH Q3A [2] , a separate guideline, ICH Q3C [11] , was developed to provide safety based guidance on the allowable limits of common residual solvents within pharmaceuticals. As there are "no should be removed to the extent possible to meet product based requirements". Additionally, ICH Q3C recommends the use of less toxic solvents. Thus, solvents that are known to be highly toxic (Class 1) should be avoided during the production of drug substances, excipients, and especially drug products, unless
In addition, some solvents with intermediate toxicity (Class 2) should also be limited from a patient safety perspective. Ideally, the least toxic solvents (Class 3) should always be used where practical. Recommended limits for all solvents may change as additional safety data become available. In addition, supporting safety data for new solvents may be added to the guidance.
Although tolerable daily intake (TDI) and acceptable daily intake (ADI) were both in common usage, ICH Q3C (11) introduced a new term, permitted daily exposure (PDE) to avoid confusion of differing values for ADI's for the same substance. In addition to avoidance of class 1 solvents, the concept of "as low as reasonably practicable" (ALARP) was introduced and is applied to class 2 solvents and often to class 3 solvents. Indeed, regulatory agencies will often use process capability arguments to drive down residual solvent levels below the safety based limits [13] derived from ICH Q3C.
Residual Elemental Impurities (ICH Q3D)
Residual elemental impurities were also mentioned in ICH Q3A [2] , but again a separate guideline, ICH Q3D (14) was developed to provide safety based guidance on the allowable limits of residual elements within pharmaceuticals. As elemental levels in the drug product should be controlled within acceptable limits" [14] .
The ICH Q3D guideline is sub-divided into three parts: the derivation and assessment of toxicity data; the establishment of a PDE for each elemental impurity derived for three different routes of administration (oral, inhaled and parenteral); and application of a risk based approach to control elemental impurities (as per ICH Q9 (12)). One difference from ICH Q3C [11] is that applicants are not expected to tighten the safety based limits based on process capability considerations, as long as the residual elemental impurities do not exceed the PDE values. However, in certain cases, levels below the PDE may be warranted when lower levels have been shown to positively impact on other critical quality attributes (CQAs) of the drug product; for example, element catalyzed drug degradation (this is particularly common with oxidative degradation mechanisms [15] ). In addition, for those elements with higher PDEs, lower limits may have to be assessed from a pharmaceutical quality (Table 4) . Table 4 : [14] .
Elemental

Classi ication Comments
1
The class 1 elements are As, Cd, Hg, and Pb. They are extremely toxic and they have limited or no use in the pharmaceutical production. Their presence in drug products typically arises from commonly used excipients that are mined, e.g. talc. These four elements require extensive evaluation during the risk assessment process. The risk assessment will determine which components require additional controls, including in some cases testing for class 1 element. However, testing should only be initiated based on risk assessments; i.e. it is not a routine requirement.
2a
2A elements have relatively high probability of occurrence in the drug product and they require extensive evaluation during the risk assessment process.
2b
The class 2B elements include Ag, Au, Ir, Os, Pd, Pt, Rh, Ru, Se and Tl. Class 2B elements show a reduced likelihood of occurrence within the drug product because of their low abundance and low potential to be co-isolated with other materials, e.g. in mined excipients. Consequently, they may be excluded from the risk assessment process unless they are intentionally added (i.e. as catalysts) during the manufacture of drug substances, excipients or other components of the drug product. ICH Q3D [14] provides a platform for developing an ICH Q9 (12) aligned risk-based control strategy to limit elemental impurities within the drug product. Although, the guidance had highlighted the risk inherent from both drug substance and excipients, the reality based on a multi-product assessment is that the risk is low. Li et al. [16] 
Residual mutagenic impurities (ICH M7)
ICH M7 [5] is focused on DNA reactive impurities that can potentially cause DNA damage, when present at low levels, and thus can potentially cause cancer in man. Importantly, other types of toxic impurities that are non-mutagenic will typically have a threshold mechanism and as such usually do not pose carcinogenic risk in man, at the levels typically seen for impurities.
A Threshold of Toxicological Concern (TTC) approach was introduced to describe an "acceptable intake for any unstudied chemical that poses a negligible risk of carcinogenicity or other methodologies that underpin the TTC are universally considered to be very conservative, as they use a simple linear extrapolation from the TD 50 dose (i.e. dose giving a 50% tumor incidence) to a 1 in 10 6 likelihood of cancer occurrence. theoretical 10 -5 excess lifetime risk of cancer can therefore be These high potency compounds were excluded from the TTC approach.
ICH M7 [5] bases acceptable intakes for mutagenic impurities on established risk assessment approaches (see ICH Q9 [12] ). As such, acceptable risk during the early development phase is established at a higher theoretically calculated risk level of approximately one additional cancer incidence per million, i.e. 1 in 10 6 risk levels. For later stages in development (Phase III) and for commercial products, the risk level is reduced to one in one hundred thousand, i.e. 1 in 10 5 risk levels. It is worth highlighting, that these risk levels represent a small theoretical increase in risk when compared to the overall lifetime incidence of developing cancer in man, which is greater than 1 in 3.
The initial risk assessment is undertaken on the drug substance synthetic pathway to identify real or potential impurities that may be reactive and thereby mutagenic in nature. In parallel, the formulation and manufacturing process are also assessed for the formation of any reactive degradants (both real and potential), that could be realistically expected to form during long term, real-time storage conditions. In silico structurebased assessments, i.e. Derek Nexus, Sarah Nexus, etc., are used for predicting mutagenicity based upon QSAR (quantitative then reviewed by toxicology experts to provide any additional understanding as to the relevance of these predictions (both positive and negative), and in the case of contradictory outcomes to understand those differences. Based on this assessment, decreasing regulatory concern (Table 5). It is anticipated that monitoring and control strategies (including analytical methods) will be less developed during earlier clinical phases, where overall development experience is of necessity limited, compared to later clinical phases and commercial manufacture. ICH M7 [5] propose a control strategy using four control options for mutagenic impurities, of these only one includes control of the mutagenic impurity on the API of in-process control; whereas, option 4 is centred on process understanding alone, typically termed "Purge Arguments" [18] .
It is should be emphasised that these established cancer risk assessments are based on lifetime exposures, i.e. 75 years. Thus, Less-Than-Lifetime (LTL) exposure based limits can be derived both during development and commercial use. LTLs can have higher acceptable intakes of mutagenic impurities and still maintain comparable risk levels, which is obviously an application of Haber's law. Therefore, the carcinogenic effect is predicated on both duration of exposure and dose.
is 15 μg/day for lifetime exposure, the less than lifetime limits (Table 6) can be increased to a daily intake of 100 μg (>1-10 years treatment duration), 200 μg (>1-12 months) or 1200μg (<1month)" [5] . This LTL approach may also be appropriate "in diseases with reduced life expectancy, limited therapeutic alternatives or chronic diseases with late onset" [19] . It is worth emphasising that exceeding the default TTC or LTL limits is not necessarily linked with an increased cancer risk in man, given the extremely conservative suppositions employed in the evolution and derivation of the TTC or LTL values. For instance, higher exposure to a potential mutagenic impurity, e.g. formaldehyde, may be reasonable when exposure metabolism, food, etc. The most likely increase in cancer incidence is actually much less than 1 in 100,000. In addition, in cases where a mutagenic compound is a non-carcinogen in a rodent bioassay, there would be no predicted increase in cancer risk. Based on all the above considerations, any exposure to an associated with an increased cancer risk for patients already exposed to the impurity. A risk assessment would determine whether any further actions would be taken In principle, ICH M7 does not apply to advanced cancer therapeutic indications (covered by ICH S9 (20) ), where the drug is itself genotoxic. ICH M7 does not apply to established including herbal medicines. Existing commercial products are also exempted, apart from where there are new safety data (including new mutagenic data) for existing impurities;
concern. However, ICH M7 does cover changes to marketed products, including new marketing applications and postapproval submissions.
Impurities in oncology products (ICH S9)
ICH S9 [20] was developed to provide guidance for nonclinical studies for the development of anticancer pharmaceuticals used in clinical trials for the treatment of patients with advanced disease and limited therapeutic options. During the development of oncology products, supporting clinical studies often involve cancer patients whose prognosis is poor and projected lifetime is short (<2 years).
As such, the guideline objectives are to facilitate and accelerate the development of these anticancer pharmaceuticals whilst protecting patients from unnecessary adverse effects. In addition, ethical use of animals, in accordance with the 3R the principles described in other ICH guidelines need to be considered in the development of oncology products; whereas, testing may diverge from other guidance are described in ICH S9.
Additionally, the dose levels used in these clinical oncology studies are often at the top end of the tolerable range [21] and often result in adverse effect dose levels. Hence, "the type, timing oncology pharmaceuticals. Historically, limits for impurities (see ICH Q3A [2] and Q3B [6] ) have been based on a negligible risk to the patient. In oncology products this consideration, whilst important, is not as important as patient wellbeing and exceeding the ICH Q3A [2]/Q3B [6] limits for impurities may be the marketing application.
This explanation should include an overview of the disease being treated, including patient prognosis, the nature of the drug itself (pharmacology, genotoxicity and carcinogenicity, etc.), the total duration of treatment, and the impact of any reduction in impurity levels on manufacturability. Furthermore, on the concentration tested in supporting nonclinical studies compared to the levels seen in clinical batches. In addition, TTC, LTL and AI/PDE limits for mutagenic impurities (see ICH M7 [5] ) be used to set higher limits. Interestingly, the guidance does not Q3B [6] limits, although this is often inferred. Impurities that are Interestingly, regulators have been very unwilling to extend the philosophy of ICH S9 [20] beyond oncology products, for instance into rare diseases [22] , where lifetime expectancy can be similarly short, i.e. <2 years and where patient expectations are equally high.
New Re lections on Impurities
Harvey et al.
[23] used a variety of chemical databases to impurity of unknown toxicity, proposed by ICH Q3A [2] (Table   law , where C=1 mg and t=75 years (i.e., 27375 days) and t' is exposure interval of 5 mg/day (i.e. 5 times higher than existing ICH Q3A limit). However, for very potent drugs with effective doses of <1mg, a 5mg/day limit for a related impurity isn't realistic from either a safety or quality perspective. Therefore, the authors also introduced a percentage cut off based on 5x the proposed limits for drug substances are 5mg or 0.7%, whichever is lower.
This allows applicants to adopt the existing ICH Q3A guideline which were developed for commercial products and apply them to development products, in much the same way that the ICH M7 guidelines allows LTL limits for mutagenic impurities, for early clinical development. For drug products, similar LTL limits for non-mutagenic impurities can be derived based on percentage limit of 0.7% need not be applied to drug products as the more potent the drug substance becomes, the lower the dose required. The authors therefore suggested a limit of 5 mg or 2%, whichever is lower, for exposure intervals of <6 months, for general drug substance impurities, i.e. non-mutagenic.
In addition to absolute amounts of unknown impurities, the other key focus is those impurities with unusually high and/ impurities constitute the greatest threat to patient safety and they have been addressed via ICH M7; there are other classes of non-mutagenic impurities that will still give cause for concern. The three principal classes of toxic impurities are (i) polyhalogenated, dibenzodioxins, dibenzofurans and biphenyls that are non-mutagenic carcinogens, which have exposure levels [24] , (ii) organophosphates or carbamates that are neurotoxins like impurities that have the potential to cause anaphylaxis and which currently do not have any threshold of concern [23].
It is worth highlighting that typical structure of impurities generated by medicinal research [26, 27] and (b) That these structural motifs (if present) would be highlighted and addressed as part of the ICH M7 risk assessment reviewed by toxicology experts".
Conclusion
Safety based impurity limits are a core consideration of all of the existing ICH Q3 guidance documents. However, there has been an evolution in the approach toward impurities since the and Q3B [6] provide general guidance on impurities in drug substances and drug products, respectively and mainly focus on absolute levels of impurities, i.e. percentage based limits; later guidance focused on individual impurity classes; i.e. residual solvents [11] , residual elemental impurities [14] and mutagenic impurities [5] and had a greater focus on daily exposure limits. In the latter cases, this led to the introduction of various impurity the introduction of LTL limits for mutagenic impurities.
LTLs are based on an application of Haber's law which states that concentration and exposure times are both critical for assessing likely safety risk to patients. Surprisingly, LTLs have Harvey et al. [23] have assessed the underpinning data behind the current "1mg or 1%, whichever is lower" limit in ICH Q3A [2] /Q3B [6] , and they found this to be based on robust science and they proposed an ancillary LTL for general impurities of 5 mg or 0.7%, whichever is lower, for clinical studies with durations of less than 6 months.
Logically, the toxicity of the parent drug substance also affects how we deal with impurities, even very toxic impurities. Thus, there is limited, if any, additional impact on patient safety for impurities where the parent drug substance is mutagenic, carcinogenic or cytotoxic. Accordingly it was recognised that for oncology products, impurity levels (even mutagenic impurities) could be controlled at higher levels. This "higher being treated, including patient prognosis, and the nature of the drug itself. Additionally, from a risk based perspective and an understanding of Haber's law, an overt focus on impurity control makes little sense if the life expectancy of the affected patient is short, i.e. less than 2 years [20] . Interestingly, there has been little regulatory appetite for widening this entirely pragmatic approach to impurity control to other therapeutic areas, where life expectancy is equally short, i.e. rare diseases [22] .
